CFO Bhavana Agrawal resigns, moves to regional role at AstraZeneca Group

Cfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹8050.00

prior close

₹8025.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-0.1% vs market

Pharmaceuticals peers, median of 165sector+0.1%+0.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

+0.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+0.3-0.1+0.1+0.1

Next day

-0.4-0.9+0.4-1.5+1.1

-2.1-1.5-0.6-2.1+0.0

-0.5-1.1+0.7-2.3+1.9

+0.7+0.2+0.5-1.6+2.3

+0.4-1.1+1.4-2.4+2.8

+0.7-1.2+1.9-2.6+3.3

15d

-1.3+3.1-4.5+0.3-1.7

-8.1+4.5-12.5-0.4-7.6

-17.6+4.5-22.1+1.3-18.9

-24.7-2.2-22.4-5.8-18.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ms. Bhavana Agrawal, Executive Director and CFO of AstraZeneca Pharma India, has resigned as CFO effective August 31, 2026, to take up a regional role within the AstraZeneca Group. She continues as Executive Director. Resignation cited as internal group transition, disclosed under SEBI LODR. She holds no shares in the company.

Likely market impact

CFO transition within parent group; routine internal move. Watch for successor announcement. No governance concerns.